Nicox First Quarter 2020 Business Update and Financial Highlights - Seite 3

As of March 31, 2020, the Nicox Group had cash and cash equivalents of €45.2 million as compared with €28.0 million at December 31, 2019.  Net revenue² for the first quarter of 2020 was €1.7 million (including €1.0 million of the milestone from Ocumension), compared to €0.4 million for the first quarter of 2019.  €14 million of the milestone received from Ocumension is classified as deferred income due to Nicox’s ongoing involvement in the development of NCX 470.

As of March 31, 2020, the Nicox Group had financial debt of €18.1 million in the form of a bond financing agreement with Kreos Capital signed in January 2019.   

Only the figure related to the cash position of the Nicox Group as of December 31, 2019 is audited; all other figures of this press release are non-audited. 

Notes
 

1. Bloomberg data, comparing the period of the weeks ending January 3, 2020 to March 27, 2020 with the period of the weeks ending October 4, 2019 to December 27, 2019 and January 1, 2019 to March 27, 2019
2. Net revenue consists of revenue from collaborations less royalty payments, which corresponds to Net profit in the consolidated statements of profit or loss

About Nicox Nicox S.A. is an ophthalmology company developing innovative solutions to help maintain vision and improve ocular health.  Nicox’s lead program in clinical development is NCX 470, a novel, second-generation nitric oxide-donating bimatoprost analog, for lowering intraocular pressure in patients with glaucoma.  The company is also developing NCX 4251, a proprietary formulation of fluticasone, for acute exacerbations of blepharitis.  Nicox generates revenue from VYZULTA in glaucoma, licensed exclusively worldwide to Bausch & Lomb, and ZERVIATE in allergic conjunctivitis, licensed in multiple geographies, including to Eyevance Pharmaceuticals, LLC, in the U.S. and Ocumension Therapeutics in the Chinese and Southeast Asian markets. 

Nicox is headquartered in Sophia Antipolis, France, is listed on Euronext Paris (Compartment B: Mid Caps; Ticker symbol: COX) and is part of the CAC Healthcare, CAC Pharma & Bio and Next 150 indexes.

For more information on Nicox, its products or pipeline, please visit: www.nicox.com. Analyst coverage